Retail REITs Show Signs Of Improvement At ICSC Convention, Report Says Jun 11

  • ID: 1818050
  • June 2011
  • Standard & Poors
1 of 2

NEW YORK (Standard & Poor's) June 8, 2011--Retail REIT prospects seemed brighter at the 2011 International Council of Shopping Centers (ICSC) global retail real estate convention, according to a report published earlier this week by Standard & Poor's Ratings Services. The retail landlords Standard & Poor's met with indicated at the conference that the amount of leasing activity was materially stronger than 2010, and most of them said they expect 2011 occupancy rates within their portfolios to exceed low levels experienced in 2009 and early 2010. "Taken together, lower vacancy rates, fewer tenant bankruptcies, little to no new development, and a recovering CMBS market support Standard & Poor's Ratings Services' view that performance for most rated retail REITs will slowly...

Action: General Comment

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our


Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.